UTP13 Antibody

What is UTP13 and what role does it play in cellular processes?

UTP13 (also known as TBL3) is a component of the Small Subunit (SSU) processome involved in ribosomal RNA processing. It belongs to the UTP-B subcomplex and participates in pre-ribosomal RNA processing and ribosome biogenesis. UTP13 uses its C-terminus to interact with UTP12 to form a tetrameric complex (UTP1-UTP21-UTP12-UTP13) within the UTP-B subcomplex . The protein contains specific N-terminal domains (1-320aa) that interact with UTP3, facilitating its nucleolar localization and function in ribosome assembly .

What are the best fixation methods for immunofluorescence studies of UTP13?

For optimal immunofluorescence detection of UTP13, consider these fixation approaches:

• Paraformaldehyde fixation (4% PFA for 15-20 minutes) preserves protein localization while maintaining antibody accessibility, ideal for studying nucleolar localization of UTP13 and co-localization with UTP3.

• For studying cytoplasmic UTP13 (in absence of UTP3), shorter fixation times (10 minutes) may better preserve cytoplasmic structures.

• Methanol fixation (-20°C for 10 minutes) can be an alternative approach that sometimes reveals epitopes masked by PFA fixation.

• A combination approach of brief PFA fixation followed by methanol can sometimes provide optimal results for detecting both cytoplasmic and nuclear UTP13.

When studying UTP13-UTP3 interactions, always include nucleolar markers like fibrillarin or NPM1 to confirm proper nucleolar preservation and localization patterns.

How should I optimize western blotting conditions for UTP13 detection?

Optimizing western blotting for UTP13 detection requires attention to several parameters:

• Sample preparation:

  • Include protease inhibitors in lysis buffers

  • Consider phosphatase inhibitors if studying post-translational modifications

  • Test different lysis conditions (RIPA vs. gentler NP-40 buffers)

• Protein separation:

  • Use 8-10% gels for optimal resolution of UTP13

  • Consider longer running times for better separation

• Transfer conditions:

  • For larger proteins, use lower methanol concentrations in transfer buffer

  • Test wet transfer conditions for optimal results

• Antibody conditions:

  • Titrate primary antibody concentration (typically starting at 1:1000)

  • Test different incubation temperatures and times

  • Include 0.1% Tween-20 in antibody solutions to reduce background

Always include appropriate controls, particularly UTP13 knockdown samples, to validate antibody specificity and performance in your experimental system.

How does UTP3 influence the nucleolar localization of UTP13?

The mechanism of UTP3-dependent nucleolar localization of UTP13 involves several key processes:

• Initial complex formation: UTP3 interacts with UTP13 in the cytoplasm through their respective N-terminal domains. Specifically, the N-terminal 1-319aa of UTP3 directly interacts with the N-terminal 1-320aa of UTP13 . This interaction is not dependent on RNA, as demonstrated by RNase treatment experiments .

• Nuclear entry: While UTP13 alone remains predominantly cytoplasmic, the UTP3-UTP13 complex can enter the nucleus . This process appears to be enhanced by UTP12, which interacts with UTP13's C-terminus. The addition of UTP12 significantly increases the co-immunoprecipitation of UTP3 by UTP13, suggesting that UTP12 stabilizes the UTP3-UTP13 complex .

• Nucleolar targeting: The nucleolar localization domain of UTP3 (contained in its C-terminal region) is essential for guiding UTP13 to the nucleolus. When UTP13 is co-expressed with only the N-terminal fragment of UTP3 (1-319aa), both proteins remain in the nucleoplasm but fail to accumulate in the nucleolus .

Experimental depletion of UTP3 through shRNA knockdown results in the loss of nucleolar localization of UTP13, confirming this dependency .

What experimental techniques are most effective for studying UTP13 protein interactions?

Several complementary techniques have proven effective for studying UTP13 interactions:

• Co-immunoprecipitation (Co-IP): This technique has successfully demonstrated interactions between UTP13 and its binding partners, particularly UTP3 . Both endogenous and tagged versions of the proteins can be used.

• GST pull-down assays: This approach has confirmed direct interaction between the N-terminal domains of UTP13 and UTP3. Specifically, GST-tagged UTP13 (1-320aa) successfully pulled down HIS-tagged UTP3 (1-319aa) .

• RNase treatment experiments: These experiments help determine whether protein-protein interactions are RNA-dependent. For UTP13 and UTP3, their interaction was not significantly affected by RNase treatment, suggesting an RNA-independent association .

• Co-immunofluorescence staining: This approach is valuable for visualizing the co-localization of UTP13 with other proteins such as UTP3 and UTP12 in different cellular compartments .

• Mass spectrometry analysis: This technique has identified multiple UTP13-interacting proteins from cytoplasmic extracts .

How can I design experiments to study the dynamic shuttling of UTP13 between cytoplasm and nucleolus?

Studying the dynamic shuttling of UTP13 between cellular compartments requires approaches that can capture protein movement in real-time:

• Live-cell imaging with fluorescent fusion proteins:

  • Generate UTP13-GFP/RFP fusion constructs, being careful with tag position to avoid interfering with localization signals

  • Use photoactivatable or photoconvertible tags to track specific populations of UTP13

  • Employ FRAP (Fluorescence Recovery After Photobleaching) to measure shuttling kinetics between compartments

• Controlled expression systems:

  • Establish inducible expression systems (such as Tet-On) for both UTP13 and UTP3

  • Monitor localization changes at various time points after induction

  • Create a system allowing sequential induction of UTP13 followed by UTP3 to observe real-time translocation

• Perturbation experiments:

  • Use targeted inhibitors of nuclear import/export

  • Generate UTP13 mutants with altered UTP3-binding capacity

  • Test effects of cell cycle inhibitors on UTP13 localization patterns

• Quantitative analysis:

  • Develop image analysis pipelines to quantify UTP13 distribution across cellular compartments

  • Consider high-content screening approaches to identify factors affecting UTP13 localization

These experimental designs should include appropriate controls, such as UTP13 mutants lacking the UTP3-binding domain and UTP3-knockdown conditions .

What is the structural relationship between UTP13 and other components of the UTP-B subcomplex?

UTP13 plays a critical role in the architecture of the UTP-B subcomplex within the SSU processome:

• Tetrameric complex: UTP13 uses its C-terminus to interact with UTP12 to form a tetrameric complex comprising UTP1-UTP21-UTP12-UTP13 within the UTP-B subcomplex .

• N-terminal interactions: While the C-terminus of UTP13 is engaged with the UTP-B subcomplex, its N-terminal domain (1-320aa) interacts with UTP3, potentially serving as a bridge between different processome components .

• Hierarchical assembly: The assembly of the UTP-B subcomplex likely follows a hierarchical pattern, with UTP13 being incorporated at a specific stage.

• Structural stability: The interaction of UTP13 with UTP12 appears to increase the stability of the entire complex, as evidenced by enhanced co-immunoprecipitation of UTP3 by UTP13 in the presence of UTP12 .

Understanding these structural relationships is crucial for interpreting antibody epitope accessibility in different experimental contexts. Depending on which region of UTP13 an antibody recognizes, certain protein-protein interactions might mask the epitope, affecting detection efficiency.

How can I validate UTP13 antibody specificity for my specific experimental conditions?

Validating antibody specificity is crucial for reliable UTP13 research. A comprehensive validation strategy includes:

• Genetic validation:

  • Generate UTP13 knockdown/knockout cells and confirm signal reduction/loss

  • Perform rescue experiments with ectopic UTP13 expression in knockout backgrounds

  • Use siRNA with non-overlapping sequences targeting UTP13 to confirm specificity

• Recombinant protein controls:

  • Test antibody against purified UTP13 protein or fragments

  • Perform peptide competition assays to block specific binding

  • Compare reactivity with closely related proteins to assess cross-reactivity

• Multi-technique validation:

  • Confirm that signals from different techniques (western blot, immunofluorescence, immunoprecipitation) align with expected results

  • Verify that molecular weight, localization pattern, and interacting partners match known UTP13 properties

• Application-specific validation:

  • For immunofluorescence: Test multiple fixation methods

  • For western blotting: Compare different lysis conditions

  • For immunoprecipitation: Optimize buffer conditions to maintain protein interactions

• UTP3-dependent localization control:

  • Since UTP13 localization is UTP3-dependent, compare antibody detection in cells with and without UTP3 expression

  • Correctly validated antibodies should detect UTP13 in the cytoplasm when UTP3 is absent and in the nucleolus when UTP3 is present

This structured validation approach ensures that your UTP13 antibody is suitable for your specific experimental conditions and applications.

What controls should be included when studying UTP13-UTP3 interactions?

When investigating UTP13-UTP3 interactions, robust controls are essential for reliable data interpretation:

• Negative controls:

  • UTP13 knockout/knockdown cells for antibody specificity validation

  • UTP3 knockout/knockdown to confirm interaction dependency

  • Immunoprecipitation with isotype-matched irrelevant antibodies

  • Pull-down with unrelated proteins of similar size/properties

• Positive controls:

  • Co-expression of known interacting partners (UTP12-UTP13)

  • Detection of established protein complexes containing UTP13

• Domain specificity controls:

  • UTP13 N-terminal domain (1-320aa) should interact with UTP3

  • UTP13 C-terminal domain should interact with UTP12

  • UTP13 mutants with alterations in interaction interfaces

• RNA dependency controls:

  • RNase treatment to distinguish direct protein-protein interactions from RNA-mediated associations

  • DNase treatment to eliminate chromatin-mediated interactions

• Localization controls:

  • Fibrillarin or NPM1 as nucleolar markers

  • Cytoplasmic markers to confirm compartmentalization

  • Nuclear membrane markers to distinguish nuclear from cytoplasmic fractions

By implementing this comprehensive control strategy, researchers can confidently establish the specificity, dynamics, and biological relevance of UTP13-UTP3 interactions while minimizing technical artifacts and misinterpretations.

How do post-translational modifications of UTP13 affect antibody recognition?

Post-translational modifications (PTMs) can significantly impact UTP13 antibody recognition, potentially leading to false-negative results or misinterpretation of data:

• Epitope masking effects:

  • PTMs directly on or adjacent to antibody epitopes can prevent antibody binding

  • Conformational changes induced by distant PTMs can alter epitope accessibility

  • Protein-protein interactions may be PTM-dependent, affecting antibody access in complexes

• Experimental strategies to address PTM interference:

  • Use multiple antibodies targeting different regions of UTP13

  • Treat samples with appropriate phosphatases or deubiquitinases before immunodetection

  • Compare antibody recognition under different cellular conditions known to alter PTM status

• PTM-specific detection approaches:

  • Employ phospho-specific antibodies if studying phosphorylation-dependent processes

  • Use PTM-enrichment strategies before mass spectrometry

  • Implement Phos-tag gels to separate phosphorylated from non-phosphorylated forms

• UTP3-dependent considerations:

  • UTP3 co-expression may alter the PTM pattern of UTP13

  • Compare detection with/without UTP3 overexpression to assess potential PTM changes

By understanding and accounting for the effects of PTMs on UTP13 antibody recognition, researchers can select appropriate detection strategies and correctly interpret experimental results, especially in studies involving complex formation or subcellular localization changes.

What experimental approaches can resolve contradictory data regarding UTP13 localization?

When facing contradictory data about UTP13 localization, several systematic approaches can help resolve discrepancies:

• Standardized detection methods:

  • Compare multiple validated UTP13 antibodies targeting different epitopes

  • Use both N- and C-terminally tagged fluorescent fusion proteins

  • Implement epitope-tagged endogenous UTP13 using CRISPR/Cas9

• Cell type and condition considerations:

  • Systematically evaluate UTP13 localization across different cell types with varying UTP3 expression levels

  • Assess localization during different cell cycle phases

  • Compare various stress conditions that might affect nucleolar integrity

• Quantitative assessment:

  • Develop clear quantification methods for subcellular distribution

  • Use colocalization coefficients for objective analysis

  • Implement single-cell analysis to account for cell-to-cell variability

• Complementary techniques:

  • Complement imaging with biochemical fractionation followed by western blotting

  • Use proximity ligation assays to verify interactions in situ

  • Employ super-resolution microscopy for fine localization patterns

• UTP3-dependent verification:

  • Create conditions with controlled UTP3 expression levels

  • Use UTP3 knockdown and overexpression to verify the UTP3-dependency of UTP13 localization

  • Analyze UTP3 mutants lacking the nucleolar localization domain to confirm mechanism

By systematically applying these approaches and carefully documenting experimental conditions, contradictory data can often be reconciled by identifying specific factors that influence UTP13 localization.